FDA Approved: PHESGO — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for PHESGO, the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf, submitted by Genentech.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• PHESGO (PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF)

Snippet

SUPPL AP for PHESGO (PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF)